155 related articles for article (PubMed ID: 29425953)
1. Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With Nasopharyngeal Carcinoma.
Wang F; Jiang C; Ye Z; Sun Q; Liu T; Xu M; Wu P; Shi K; Long B; Fu Z; Jiang Y
Transl Oncol; 2018 Apr; 11(2):338-345. PubMed ID: 29425953
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Wang F; Jiang C; Ye Z; Sun Q; Liu T; Xu M; Wu P; Shi K; Long B; Rihito A; Masoto S; Fu Z
Oncotarget; 2017 Sep; 8(43):75544-75556. PubMed ID: 29088889
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution.
Fangzheng W; Chuner J; Zhiming Y; Tongxin L; Fengqin Y; Lei W; Bin L; Fujun H; Ming C; Weifeng Q; Zhenfu F
Oncol Res; 2018 Mar; 26(2):277-287. PubMed ID: 29046165
[TBL] [Abstract][Full Text] [Related]
4. Treatment Outcomes of 257 Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Nimotuzumab Plus Intensity-Modulated Radiotherapy with or without Chemotherapy: A Single-Institution Experience.
Wang F; Jiang C; Ye Z; Liu T; Sun Q; Yan F; Qin W; Fu Z; Jiang Y
Transl Oncol; 2018 Feb; 11(1):65-73. PubMed ID: 29202278
[TBL] [Abstract][Full Text] [Related]
5. A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma.
Li HM; Li P; Qian YJ; Wu X; Xie L; Wang F; Zhang H; Liu L
BMC Cancer; 2016 Dec; 16(1):946. PubMed ID: 27955638
[TBL] [Abstract][Full Text] [Related]
6. Induction plus adjuvant chemotherapy, combined treatment with nimotuzumab, and intensity-modulated radiation therapy for N3 stage nasopharyngeal carcinoma: A pilot study.
Zhou L; Lin J; Chen J; Zhang S
J Cancer Res Ther; 2021 Dec; 17(7):1730-1735. PubMed ID: 35381746
[TBL] [Abstract][Full Text] [Related]
7. Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
Zhai RP; Ying HM; Kong FF; Du CR; Huang S; Zhou JJ; Hu CS
Onco Targets Ther; 2015; 8():3383-90. PubMed ID: 26604795
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of concurrent chemoradiotherapy combined with nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma: A pilot study.
Zhang S; Huang X; Zhou L; Lin S
Medicine (Baltimore); 2018 Sep; 97(38):e12503. PubMed ID: 30235761
[TBL] [Abstract][Full Text] [Related]
9. Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma.
Huang J; Zou Q; Qian D; Zhou L; Yang B; Chu J; Pang Q; Wang K; Zhang F
Onco Targets Ther; 2017; 10():5835-5841. PubMed ID: 29263680
[TBL] [Abstract][Full Text] [Related]
10. An open-label, single-arm phase II clinical study of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma.
Zhang S; Huang X; Zhou L; Wu G; Lin J; Yang S; Chen J; Lin S
J BUON; 2018; 23(6):1656-1661. PubMed ID: 30610791
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma.
Fangzheng W; Quanquan S; Chuner J; Lei W; Fengqin Y; Zhimin Y; Tongxin L; Min X; Peng W; Haitao J; Aizawa R; Sakamoto M; Yuezhen W; Zhenfu F
Oncotarget; 2017 Nov; 8(57):96798-96808. PubMed ID: 29228572
[TBL] [Abstract][Full Text] [Related]
12. Concurrent chemoradiotherapy combined with nimotuzumab in stage III-IVa nasopharyngeal carcinoma: a retrospective analysis.
Cai Z; Chen D; Qiu W; Liang C; Huang Y; Zhou J; Zhan Z; Xiang Y; Guo X; Lv X
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2327-2344. PubMed ID: 36289067
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with or without nimotuzumab in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study.
Yang Z; Zuo Q; Liu R; Wu H; Xiong L; Jia J; Xiang Z
BMC Cancer; 2023 Nov; 23(1):1140. PubMed ID: 37996813
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
[TBL] [Abstract][Full Text] [Related]
15. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
[TBL] [Abstract][Full Text] [Related]
16. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study.
Wu F; Wang R; Lu H; Wei B; Feng G; Li G; Liu M; Yan H; Zhu J; Zhang Y; Hu K
Radiother Oncol; 2014 Jul; 112(1):106-11. PubMed ID: 24933452
[TBL] [Abstract][Full Text] [Related]
17. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.
Li Y; Chen QY; Tang LQ; Liu LT; Guo SS; Guo L; Mo HY; Chen MY; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Shao JY; Sun Y; Tan J; Chen S; Ma J; Zhao C; Mai HQ
BMC Cancer; 2017 Aug; 17(1):567. PubMed ID: 28836950
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma.
Xu YC; Chen KH; Liang ZG; Zhu XD
Front Oncol; 2022; 12():843675. PubMed ID: 35903695
[TBL] [Abstract][Full Text] [Related]
20. Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis.
Wang F; Sun Q; Jiang C; Liu T; Rihito A; Masoto S; Wang Y; Fu Z; Chen M
J Cancer; 2018; 9(3):594-603. PubMed ID: 29483965
[No Abstract] [Full Text] [Related]
[Next] [New Search]
